.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,952,029

« Back to Dashboard

Details for Patent: 8,952,029

Title:Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
Inventor(s): Eller; Mark (Redwood City, CA)
Assignee: Jazz Pharmaceuticals Ireland Limited (Dublin, IE)
Filing Date:Apr 29, 2013
Application Number:13/873,000
Claims:1. A method for treating a patient who is suffering from excessive daytime sleepiness, cataplexy, sleep paralysis, apnea, narcolepsy, sleep time disturbances, hypnagogic hallucinations, sleep arousal, insomnia, or nocturnal myoclonus with gamma-hydroxybutyrate (GHB) or a salt thereof, said method comprising: orally administering to the patient in need of treatment at least a 5% increase in an effective dosage amount between 1 gram and 10 grams per day of the GHB or salt thereof when the patient is receiving a concomitant administration of diclofenac or a salt thereof.

2. The method in accordance with claim 1, wherein there is at least about a 15% increase in the effective dosage amount of the GHB or salt thereof normally given to the patient.

3. The method in accordance with claim 2, wherein the dose of GHB or salt thereof given to the patient without concomitant administration of diclofenac is a range between 4.5 to 9 grams per day.

4. The method in accordance with claim 1, wherein the effective dosage amount is increased between the range of about 5% to 10%, about 10% to 15%, about 15% to 20%, about 20% to 25%, about 25% to 30%, about 30% to 35%, about 35% to 40%, about 40% to 45%, or about 45% to 50%, relative to the dose of the GHB or salt thereof normally given to the patient.

5. The method in accordance with claim 1, wherein the patient is suffering from narcolepsy.

6. The method in accordance with claim 1, wherein the effective dosage amount is increased from a range of between 4.5 to 9 grams per day.

7. The method in accordance with claim 1, wherein the amount of GHB or salt thereof administered to the patient is between 7 grams and 12 grams per day after the increase.

8. The method in accordance with claim 1, wherein the amount of GHB or salt thereof administered to the patient is between 9 grams and 11 grams per day after the increase.

9. A method of safely administering GHB or a salt thereof for excessive daytime sleepiness, cataplexy, sleep paralysis, apnea, narcolepsy, sleep time disturbances, hypnagogic hallucinations, sleep arousal, insomnia, or nocturnal myoclonus in a human patient who is being administered GHB, said method comprising: determining if the patient has taken, or will take, a concomitant dose of diclofenac or a salt thereof; and orally administering an increased amount of the GHB or salt thereof to the patient wherein the increase is at least 5% compared to a dose without concomitant administration of diclofenac or salt thereof that is between 1 gram and 10 grams per day.

10. The method in accordance with claim 9, wherein the amount of GHB or salt thereof administered to the patient is increased at least 15%.

11. The method in accordance with claim 9, wherein the diclofenac or salt thereof is administered within two weeks of administration of the GHB or salt thereof.

12. The method in accordance with claim 9, wherein the diclofenac or salt thereof is administered within three days of administration of the GHB or salt thereof.

13. The method in accordance with claim 9, wherein the patient is suffering from narcolepsy.

14. The method in accordance with claim 9, further comprising recommending to increase the starting dose by 20%.

15. A method for treating a patient who is suffering from narcolepsy, said method comprising: administering a therapeutically effective amount of a formulation containing a GHB salt to a patient at between 1 gram and 10 grams per day and at a concentration of between 350 and 750 mg/ml with a pH of between 6 and 10; determining if the patient is also being administered diclofenac or a salt thereof; warning of a potential drug/drug interaction due to the combination of diclofenac or a salt thereof and the GHB salt; and recommending increasing the dose of the GHB salt at least 15%.

16. The method in accordance with claim 15, wherein the diclofenac or salt thereof is administered within two weeks of administration of the GHB salt.

17. The method in accordance with claim 15, wherein the diclofenac or a salt thereof is administered within three days of administration of the GHB salt.

18. The method in accordance with claim 15, wherein the GHB salt is administered at a concentration of between 450 to 550 mg/ml.

19. The method in accordance with claim 18, further comprising adding water to the GHB salt formulation.

20. The method in accordance with claim 15, wherein the GHB salt formulation has a pH between 6.5 and 8.

21. The method in accordance with claim 15, further comprising administering the increased dose of the GHB salt to the patient.

22. The method in accordance with claim 15, wherein the GHB salt comprises a single salt or a mixture of salts of GHB selected from the group consisting of a sodium salt of hydroxybutyrate (Na.cndot.GHB), a potassium salt of gamma-hydroxybutyrate (K.cndot.GHB), a magnesium salt of gamma-hydroxybutyrate (Mg.cndot.(GHB).sub.2), and a calcium salt of gamma-hydroxybutyrate (Ca.cndot.(GHB).sub.2).

23. The method in accordance with claim 15, wherein the dose of GHB or salt thereof without concomitant administration of diclofenac is a range between 4.5 to 9 grams per day.

24. The method in accordance with claim 15, comprising recommending increasing a starting dose at least 20%.

25. The method in accordance with claim 15, further comprising adding water to the GHB salt formulation.

26. The method in accordance with claim 15, further comprising optionally diluting the GHB salt formulation from a starting concentration of between 350 and 750 mg/ml with a pH of between 6 and 10.

27. A method for treating a patient who is suffering from narcolepsy, said method comprising: orally administering a therapeutically effective amount of a formulation containing a GHB salt; determining if the patient is also being administered diclofenac or salt thereof; recommending a 20% increase in the starting dose of the GHB salt such that the amount that the patient is administered is increased to about 5.4 grams GHB per day.

28. The method in accordance with claim 27, further comprising optionally diluting the GHB salt formulation from a starting concentration of between 350 and 750 mg/ml with a pH of between 6 and 10.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc